Axis Securities Report Highlights Positive Trends for Q2 FY25 The Indian pharmaceutical industry is poised for a robust year, with revenue growth projected at 8.5% year-on-year (YoY) for the second quarter of FY25, driven primarily by domestic formulations and strategic niche launches in the US market.
The Three day International Exhibition For Pharma And Healthcare Exhibition (IPHEX 2024) begins More than 400 Major Indian pharma companies to showcase their pharmaceutical products and Technologies at the expo More than 400 foreign buyers from across the world to attend .India exported pharma products worth
Healthy Growth in FDI and Digital Initiatives further fueling growth of Domestic Pharma Industry India’s $42 billion pharmaceutical sector is heavily dependent on China for key active pharmaceutical ingredients or API — chemicals that are responsible for the therapeutic effect of drugs. Various estimates put India’s dependence
